Basic Information
| LncRNA/CircRNA Name | LINC01589 |
| Synonyms | NA |
| Region | GRCh38_22:45604432-45605621 |
| Ensemble | ENSG00000238120 |
| Refseq | NR_131244 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | qPCR |
| Sample | pancreatic ductal adenocarcinoma cell lines (BxPC-3,PANC-1, AsPC-1, and CFPAC-1) |
| Expression Pattern | up-regulated |
| Function Description | LINC01589 and LINC00960 showed a profoundly increased expression and turned out to be independently correlated with the patients??verall survival in pancreatic cancer cells. |
| Pubmed ID | 29923223 |
| Year | 2018 |
| Title | Orchestrating a Biomarker Panel With lncRNAs and mRNAs for Predicting Survival in Pancreatic Ductal Adenocarcinoma |
External Links
| Links for LINC01589 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |